Bronchogen Reconstitution Calculator

Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu (AEDL), a Khavinson short peptide bioregulator developed for bronchial/lung tissue. The strongest data are animal: in rats with NO2-induced COPD, a 1-month course normalized bronchoalveolar lavage cell composition, suppressed pro-inflammatory cytokines and neutrophilic inflammation, and reversed structural remodeling (goblet cell hyperplasia, squamous metaplasia, lymphocytic infiltration, and emphysema), with restoration of ciliated cells, secretory IgA, and surfactant protein B (animal).

In human bronchial epithelial cell cultures, bronchogen restored expression of the differentiation markers CXCL12 and Hoxa3 that decline in aged (late-passage) cells, with stronger effect in older cultures (in-vitro). Rat lung explants from both young and aged donors responded at 0.05 ng/ml (in-vitro). No human RCTs exist; typical community dosing is 0.5–2 mg/day subcutaneous (SC) (community protocol).

No. Bronchogen has no FDA approval, no GRAS status, and no EMA or other major-regulator drug license. It is distributed as a research peptide or compounded product. The evidence base is entirely preclinical: rat disease models, organotypic tissue culture, and human cell-line work. Any human use is off-label and outside validated safety data.

No human head-to-head comparison exists. The published rat studies administered the peptide as a course but abstracts do not specify route. Bronchogen penetrates cell membranes and localizes in the nucleus, so it is not dependent on a lung-specific delivery route (in-vitro). Community practice uses both injectable (subcutaneous) and intranasal routes; the compound is sold in injectable form (community protocol). Rationale: intranasal/inhaled delivery concentrates peptide at the bronchial epithelium where the rat data show effects; subcutaneous delivery provides reliable systemic exposure. Practitioner consensus favors 0.5–2 mg/day subcutaneous (SC), 10–20 days per course.

Published rat work used a 1-month continuous course that reversed established COPD remodeling, with no adverse signals reported. Community protocols are cyclic rather than continuous: 10–20 days on, then an interval of 1–6 months (community protocol). This cycled pattern mirrors the bioregulator model (the peptide's differentiation-promoting effect is most pronounced in aged, hypofunctional tissue, suggesting pulse dosing rather than chronic use (in-vitro). No human long-term safety data exists; extended continuous use is unsupported.

No. There are no reproductive-safety, embryotoxicity, or lactation studies. Mechanistically, bronchogen binds site-specifically to DNA and histones and alters gene-expression patterns; a compound capable of epigenetic modulation is a poor candidate for use during pregnancy. Discontinue before conception attempts (practitioner consensus).

They differ by one residue: bronchogen is Ala-Glu-Asp-Leu; Epitalon is Ala-Glu-Asp-Gly. Tissue specificity is the decisive difference. In side-by-side cell-culture testing, bronchogen stimulated differentiation markers only in bronchial epithelial cells, pancragen only in pancreatic cells, and vesugen only in fibroblasts (in-vitro). At the DNA level, bronchogen preferentially binds CTG-containing sequences, while Epitalon prefers CAG-containing sequences, giving them distinct target-site profiles. Both stimulated growth in plant callus models, confirming activity but not tissue selectivity. Select by target tissue: bronchogen for lung/bronchial repair; Epitalon for pineal/aging programs.

Bronchogen acts as a DNA- and histone-interacting gene regulator, not a receptor agonist. It raises DNA melting temperature by 3.1°C at a molar ratio of 0.01–0.055, stabilizing the double helix and binding both strands (in-vitro). It binds histones H1, H2B, H3, and H4 site-specifically, and binds CNG/CTG-containing oligonucleotides, discriminating even cytosine methylation status. Downstream, it restores tissue-specific differentiation factor expression (CXCL12, Hoxa3) in bronchial epithelium, and in the COPD rat model it normalized inflammatory cytokines and restored epithelial structure and function. The working model is epigenetic: peptide binding to chromatin alters differentiation factor transcription, shifting bronchial epithelium away from hypersecretory/metaplastic states toward functional ciliated epithelium (mechanistic).

No compound-specific stability data exist in the literature. Standard peptide handling applies (community protocol): store lyophilized powder frozen at −20°C long-term; after reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 20–30 days; do not freeze-thaw repeatedly. Vendor-supplied vials should indicate reconstitution volume (commonly 1–2 ml for a 5–10 mg vial, yielding 50–100 mcg per 0.01 ml depending on concentration), verify arithmetic per vial (community protocol).